Research programme: fibrosis therapeutics - Macrophage Therapeutics
Latest Information Update: 22 Jul 2024
At a glance
- Originator Macrophage Therapeutics
- Class Antifibrotics
- Mechanism of Action Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 08 Jul 2024 Preclinical trials in Fibrosis in USA (Parenteral) prior to July 2024 (Macrophage Therapeutics pipeline, July 2024)